CDR3 develops stem cell-based immunotherapies to cure HPV-related cancers using chimeric antigen receptors or chronic viral infections using T cell receptors.


Today, we lack cures for most virus-related cancers and chronic viral infections, especially from human papillomavirus, or HPV, and cytomegalovirus, or CMV, which can be fatal for those with weakened immune systems. CDR3’s stem cell-based treatments target HPV-associated cancers, a $16.3B market in 2018 growing at 4.5% yearly, and chronic viral infections, a rapidly growing market estimated to reach $44.2B by 2026 — with chronic CMV alone a $1.2B market in 2020 growing at 12.3% yearly.


CDR3’s patented technology alters blood stem cells to add chimeric antigen receptors (CARs) or T cell receptors (TCRs) that enable the body’s natural defenses to target virus-associated cancers. These stem cells engraft in bone marrow and develop, normally and continuously, into T cells. Isolating a patient’s own cells and infusing the CAR/TCR gene therapy creates a permanent source of T cells expressing the CAR/TCR, avoiding the high cost and significant limitations of current T cell therapy approaches.


  • Stem cell-based approach
  • Limited manipulation and cell expansion
  • Long-term engraftment
  • Cells develop naturally in the body
  • Produces persistent, functional T cells

Development Stage:

  • Pre-clinical

Patents Issued:

  • "Recombinant human progenitor cells, engineered human thymocytes, and engineered human T-cells" (2016), US 9,228,007 B1
  • "Engineering antiviral T-cell immunity through stem cells and chimeric antigen receptors" (2018), US 9,951,118 B2
  • "Protective chimeric antigen receptor stem cell gene therapy for viral infection" (2018), US 2020/0061117 A1
  • "Chimeric antigen receptors against human cytomegalovirus" (2020), PCT/US2020/055 1 94

Select Publications:



Back to Top